"The federal government's campaign could discourage potential quitters who don't want to spend money on quitting aids or don't like the idea of treating their nicotine addiction with more nicotine."
What, in addition to $6,000 does the governor of Texas have to gain by issuing an order REQUIRING all Texas 11 year old girls to be vaccinated?
These illegal practices are the secret behind this toxic drug–Zyprexa– becoming a blockbuster seller.
Today's news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
Today’s news reports about an increase suicide rate in 2004 offer an opportunity to witness how the media unwittingly disseminates pharmaceutical industry generated propaganda.
American preteen girls have been designated to pay the price by exposing their bodies to risks of harm.
In essence FDA proposals merely change the seating arrangement on the deck of the sinking Titanic. Eli Lilly announced that it intends to seek FDA approval for a long-lasting injectable form of Zyprexa (taken once a month).
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
To gain insight into how a pharmaceutical giant is revving up itsr troops to lobby Congress against the legislation. See Pfizer CEO’s directive to the entire staff exhorting them to mobilize and lobby Congress to vote against drug price controls. http://www.pfizerfactfiction.com/mma/flash.html
Readers of the New England Journal of Medicine should be forewarned: The information in the pages of the NEJM is tainted by industry influence, its professional and scientific integrity are tainted.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
